Dr Anna Wilkins’ group is investigating how to target the tumour microenvironment of bladder and prostate cancer to prevent treatment resistance, especially to radiation given with curative intent.

New research has identified a way to predict resistance to a cancer drug commonly used to treat advanced prostate cancer. Using samples from more than 200 men, researchers found a significant ...

The Institute of Cancer Research, London, has received the highest national honour in UK further and higher education for its pioneering radiotherapy research. The Queen Elizabeth Prizes for Higher ...

Today, the first men have been invited to join the ambitious £42 million TRANSFORM screening trial, kicking off the biggest prostate cancer screening study in a generation. The trial will test the ...

We've selected a range of discoveries from 2024/25 – chosen because they illustrate the quality and breadth of our basic, translational and clinical research and our ambitions under the ICR's research ...

Scientists have uncovered a protein that acts like a ‘suit of armour’ for cancer cells, shielding them from hostile environments and allowing one of the deadliest forms of skin cancer to spread ...

Although cancer is not usually inherited, certain types, including breast and ovarian, can be triggered by inherited gene faults, meaning they can run in families. Now that we can test for these ...

Up to two in five advanced prostate cancer patients could be treated with a combination of two targeted drugs, according to new research. Findings by a team of scientists at The Institute of Cancer ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to new research. The nationwide TORPEdO trial funded by ...

There have been plenty of ups and downs in my cancer journey, but one thing that has made my experience different is the way my brain works. I’m what you might call neurodiverse, with ADHD and ...